

Overcoming Nursing Management Challenges in Metastatic Castration-Resistant Prostate Cancer

i3 Health designates this live activity for a maximum of 1.0 contact hour. Participants should claim only the credit commensurate with the extent of their participation in the activity. For questions about your NCPD credit, contact i3 Health at support@i3Health.com.

Please hand this to an i3 Health representative or bring it to the i3 Health booth.

You may also use the QR code available in the presentation to complete the evaluation. Please only choose 1 format to complete.



Date: 9/10/2022 Location: GLAONS Course #: 188CRPC

Name (please print) _____ Degree _____ # Years in practice _____

E-mail (where we'll send your NCPD certificate) _____ # Pts with prostate cancer /month _____

Select all that apply: RN NP CRNP AOCNP® CNS OCN® Other: _____

***I attest that I have completed this NCPD activity** _____ ***Actual time attended (up to 1.0 hour)** _____

Signature

***REQUIRED FIELDS: SIGNATURE AND ACTUAL TIME ATTENDED MUST BE COMPLETED IN ORDER TO RECEIVE A CERTIFICATE FOR THIS NCPD-APPROVED ACTIVITY**

Your feedback is critical to future course development. Please take a few minutes to complete this evaluation.

The presentation was: Excellent Very Good Good Fair Poor

The presentation was **free from** commercial bias: Yes No If No, please explain: _____

This activity supported achievement of each of the following learning objectives:

a. Evaluate the diagnosis and staging of metastatic castration-resistant prostate cancer (CRPC)	<input type="radio"/> Strongly agree <input type="radio"/> Agree <input type="radio"/> No opinion <input type="radio"/> Disagree <input type="radio"/> Strongly disagree
b. Appraise the efficacy and safety profiles of novel therapies for metastatic CRPC as elucidated by recent clinical trials	<input type="radio"/> Strongly agree <input type="radio"/> Agree <input type="radio"/> No opinion <input type="radio"/> Disagree <input type="radio"/> Strongly disagree
c. Devise strategies to manage drug interactions and adverse events associated with novel therapies for metastatic CRPC	<input type="radio"/> Strongly agree <input type="radio"/> Agree <input type="radio"/> No opinion <input type="radio"/> Disagree <input type="radio"/> Strongly disagree

My knowledge of CRPC improved as a result of this activity. Strongly agree Agree No opinion Disagree Strongly disagree

Based on the information I learned during this activity, I feel more confident in treating patients with metastatic CRPC within my practice.

Strongly agree Agree No opinion Disagree Strongly disagree

Knowledge acquired from this activity will be utilized to improve the outcomes of my patients.

Strongly agree Agree No opinion Disagree Strongly disagree

I plan to make the following change(s) to my practice. **Please check all that apply:**

- More likely to counsel patients that prostate cancer staging includes tumor, nodal, and metastatic factors in addition to PSA levels and Gleason score
- More likely to counsel patients with prostate cancer about the indications for somatic and germline testing
- More likely to suggest olaparib for patients with metastatic CRPC and at least 1 mutation in a homologous recombination repair gene
- More likely to suggest pembrolizumab for patients with MSI-high or dMMR tumors after progression with either docetaxel or novel hormonal therapy
- More likely to monitor for neutropenia in patients receiving cabazitaxel
- More likely to refer patients to the pharmacy team for counsel about the risks of food-drug and herb-drug interactions through CYP enzymes in the liver
- More likely to monitor patients taking apalutamide with other drugs for drug-drug interactions
- More likely to refer patients with CRPC to clinical trials

What barrier(s) do you face in your practice that impact your ability to provide optimal care? **Please check all that apply:**

- Cost Time constraints Staff/system resources Reimbursement/insurance issues Organizational/institutional limitations
- Lack of applicable guidelines for my current practice/patients Conflicting evidence Patient adherence/compliance issues
- Treatment-related adverse events Other (please explain): _____

What specific action(s) do you plan to take as a result of participating in this activity? **Please check all that apply:**

- Share the activity with colleagues
- Read national guidelines (eg, NCCN) on managing CRPC to enhance my clinical competence
- Review the activity slide set to enhance my clinical competence
- Review and/or recommend modifications to my institution's protocols/practice guidelines
- Request further education on the topic with my institution's educational coordinator
- Discuss related concerns with my mentor/attending faculty about managing CRPC in my practice
- Align my patient education strategies with national guidelines/published evidence
- Consider becoming involved in CRPC research/clinical trials
- Other (please explain): _____

How will you change how you work as a team member as a result of participating in this activity? Please check all that apply:

- Suggest that further education on this topic be shared with team members
- Review and/or recommend modifications to team protocols
- Discuss studies mentioned in the activity with my team to stimulate discussion/debate
- Clarify understanding of team roles
- Improve communication with team members
- I do not plan to change how I work as a team member as a result of this activity
- Other (please explain): _____